Barricade Therapeutics has received a $14M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support Phase 1 clinical trials for its innovative therapeutic candidate, BT-1501, targeting APCmut advanced colorectal cancer (CRC). This funding builds on $5.9M previously raised and underscores the potential of BT-1501, which leverages the TASIN platform technology licensed from UT Southwestern Medical Center.
BT-1501 has shown promise in preclinical studies, significantly reducing tumor growth with minimal toxicity, offering hope as a more effective, less invasive treatment for metastatic CRC. With an FDA IND application expected by mid-2025, Phase 1 trials aim to evaluate the safety, tolerability, and pharmacokinetics in patients who have exhausted standard care options. Results from initial dosing are anticipated within 10 months of trial initiation. This milestone highlights the progress of targeted cancer therapies addressing unmet medical needs.